4D Molecular Therapeutics
The company is a biotechnology firm focused on developing therapeutics for retinal diseases and cystic fibrosis, with products in advanced stages of clinical development.
Headquarters
Emeryville, California, United States
Company Size
51-200 employees
Founded
2013
4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company that designs, develops, and commercializes gene therapies for serious, unmet medical conditions. Using a proprietary AAV capsid engineering and targeted delivery platform, 4DMT creates vectors optimized for tissue specificity, potency, and manufacturability to improve safety and therapeutic benefit. The company focuses on translational programs across ocular, neuromuscular, central nervous system, and cardiopulmonary indications and partners to advance candidates toward clinical and commercial development.
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
2 weeks ago
FDMT: Rapid phase 3 progress and strong market interest position 4D-150 for global commercialization
2 days ago
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Rating of "Moderate Buy" by Brokerages
1 week ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for 4D Molecular Therapeutics.
Biotech 4DMT heads to three March healthcare investor conferences
3 weeks ago
Senior Manager, Data Management
Spyre Therapeutics
Manager/Senior Manager, Clinical Data Management
Beam Therapeutics
Senior Director Data Management (Contract)
Jasper Therapeutics
Clinical Data Manager (6-month contract)
Zymeworks
Director, Clinical Data Management
Bristol Myers Squibb
Associate Director, Clinical Quality Assurance
Dyne Therapeutics